Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries

Haemophilia

Volumn 15, Issue 5, 2009, Pages 1083-1089

  Bonnet, P O ^a   Yoon, B S ^a   Wong, W Y ^a   Boswell, Kim ^b   Ewenstein, B M ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b XCENDA   (United States)

Author keywords

Activated prothrombin complex concentrate; Cost; Haemophilia; Inhibitors; Recombinant factor VIIa; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST MINIMIZATION ANALYSIS; DRUG COST; HEMOPHILIA; HEMOPHILIA A; HUMAN; MONOTHERAPY; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; HEALTH CARE COSTS; HEMOPHILIA A; HEMOSTATICS; HUMANS; MODELS, ECONOMIC; ORTHOPEDICS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 69949111712     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02038.x     Document Type: Article

References (38)

1. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. WHO Bulletin OMS 1995; 73: 691-701.
2. Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA ®) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-9.
3. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-31.
4. Turecek PL, Varadi K, Keil B et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33: 16-22.
5. Quintana-Molina M, Martínez-Bahamonde F, González-García E et al. Surgery in haemophilic patients with inhibitor: 20years of experience. Haemophilia 2004; 10 (Suppl. 2): 30-40.
6. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
7. Habermann B, Hochmuth K, Hovy L, Scharrer I, Kurth AHA. Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): A single centre experience. Haemophilia 2004; 10: 705-12.
8. Hvid I, Rodriguez-Merchan EC. Orthopaedic surgery in haemophilic patients with inhibitors: An overview. Haemophilia 2002; 8: 288-91.
9. Konkle BA, Nelson C, Forsyth A, Humes E. Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia 2002; 8: 706-10.
10. Goddard N. Case studies: Orthopaedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia 2005; 11 (Suppl. 1): 32-7.
11. Faradji A, Bonnomet F, Lecocq J et al. Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven): A new case report and review of the literature. Haemophilia 2001; 7: 321-6.
12. Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A review of the literature. Haemophilia 2008; 14: 233-41.
13. Baghaei F, Boberg P, Wollter I, Stigendal L. Case Report on Successful Use of Activated Prothrombin Complex Concentrate Feiba in Orthopedic Surgery on Two Patients with Factor VIII Inhibitors. Abstract presented at the XXth Congress of the International Society on Thrombosis and Haemostasis; Sidney, Australia, 2005.
14. Ménart C, Lalain JJ, Lienhart A, Dechavanne M, Négrier C. Safety and efficacy of three arthroscopic procedures using Holmium: Yag laser in two high-responder haemophiliacs. Haemophilia 1999; 5: 278-81.
15. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, Hernández-Navarro F. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia 2007; 13: 613-9.
16. Ludlam C. Identifying and managing inhibitor patients requiring orthopaedic surgery-the multidisciplinary team approach. Haemophilia 2005; 11 (Suppl. 1): 7-10.
17. Solimeno LP, Perfetto OS, Pasta G, Santagostino E. Total joint replacement in patients with inhibitors. Haemophilia 2006; 12 (Suppl. 3): 113-6.
18. Feiba VH. Anti-Inhibitor Coagulant Complex (Vapor Heated) [package insert]. Westlake Village, CA: Baxter, 2005.
19. NovoSeven [package insert]. Princeton, NJ: Novo Nordisk Inc., 2006.
20. Ballal RD, Botteman MR, Foley I, Stephens JM, Wilke CT, Joshi AV. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: Exploratory results via literature-based modeling. Curr Med Res Opin 2008; 24: 753-68.
21. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005; 11 (Suppl. 1): 11-7.
22. Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): A pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007; 25: 1007-29.
23. Botteman MF, Ballal R, Joshi AV, Stephens JM. Lifetime economic value of orthopedic surgery with recombinant activated factor VII in hemophilia patients with inhibitors. [abstract no. PHM6] Value Health. 2007; 10: A154. Plus poster presented at the 12th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2007 May 19-23; Arlington (VA).
24. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: A review of the literature. Epilepsia 2002; 43 (Suppl. 4): 10-7.
25. Thomson Micromedex. Red Book™ for Windows [computer program]. Greenwood Village, Co: Thomson Reuters, 2006.
26. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. J Thromb Haemost 1997; 77: 1113-9.
27. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
28. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. J Thromb Haemost 1998; 80: 912-8.
29. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor bypassing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
30. Astermark J, Donfield SM, DiMichele D et al. A randomization comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
31. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: Mode of action. Haemophilia 2004; 10 (Suppl. 2): 3-9.
32. Turecek PL, Varadi K, Gritsch H et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77 (Suppl. 1): 72-9.
33. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003; 49: 14-21.
34. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-57.
35. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
36. Gringeri A, Mantovani LG, Scalone L, Mannuci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
37. Perez R, Martinez ML, Pinero A, Sosa R. Sequential treatment with bolus and continuous infusion of recombinant factor VIIa for hip arthroplasty in a patient with haemophilia A and inhibitor. Haemophilia 2002; 8: 822-5.
38. Ludlam CA. The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 1): 13-8.